Podstawowe statystyki
| LEI | 529900B9W875XDZXTM97 |
| CIK | 1055726 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Inovio Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Na tej stronie znajduje się pełna, chronologiczna lista zgłoszeń SEC, z wyłączeniem zgłoszeń własności, które udostępniamy gdzie indziej.
| May 26, 2026 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 INOVIO PHARMACEUTICALS, INC. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.001 par value per share, Amended and Restated 2023 Omnibus Incentive Plan Other 10,200, |
|
| May 26, 2026 |
EX-4.5 Exhibit 4.5 INOVIO PHARMACEUTICALS, INC. AMENDED AND RESTATED 2023 OMNIBUS INCENTIVE PLAN Adopted by the Board of Directors: March 4, 2026 Approved by Stockholders: May 20, 2026 INOVIO PHARMACEUTICALS, INC. AMENDED AND RESTATED 2023 OMNIBUS INCENTIVE PLAN 1. GENERAL. (a) Prior Plan. The Company originally adopted the Inovio Pharmaceuticals, Inc. 2023 Omnibus Incentive Plan effective as of t |
|
| May 26, 2026 |
As filed with the Securities and Exchange Commission on May 22, 2026 S-8 As filed with the Securities and Exchange Commission on May 22, 2026 Registration No. |
|
| May 20, 2026 |
AMENDMENT TO AMENDED AND RESTATED INOVIO PHARMACEUTICALS, INC. ADOPTED: MAY 19, 2026 EX-3.1 Exhibit 3.1 AMENDMENT TO AMENDED AND RESTATED BYLAWS OF INOVIO PHARMACEUTICALS, INC. ADOPTED: MAY 19, 2026 The Amended and Restated Bylaws (the “Bylaws”) of INOVIO Pharmaceuticals, Inc., a Delaware corporation (the “Company”), are hereby amended as follows: Article III, Section 3.5 of the Bylaws is hereby amended by adding the following new subsection (e) at the end thereof: “(e) At every m |
|
| May 20, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2026 Inovio Pharmaceuticals, Inc. |
|
| May 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, |
|
| May 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2026 Inovio Pharmaceuticals, Inc. |
|
| May 13, 2026 |
INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights Exhibit 99.1 INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights •Biologics License Application (BLA) for INO-3107 actively being reviewed under the accelerated approval program by the U.S. Food and Drug Administration (FDA) with a target Prescription Drug User Fee Act (PDUFA) date of October 30, 2026 •Commercial readiness plans continue to advance in anticipation of |
|
| April 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| April 6, 2026 |
EX-4.2 Exhibit 4.2 WARRANT TO PURCHASE COMMON STOCK INOVIO PHARMACEUTICALS, INC. Warrant Shares: [ ] Issue Date: April 6, 2026 THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Da |
|
| April 6, 2026 |
INOVIO Announces Proposed Public Offering EX-99.1 Exhibit 99.1 INOVIO Announces Proposed Public Offering PLYMOUTH MEETING, PA – April 1, 2026 /PRNewswire/ – INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it intends to offer and sell shares of its comm |
|
| April 6, 2026 |
EX-4.3 Exhibit 4.3 WARRANT TO PURCHASE COMMON STOCK INOVIO PHARMACEUTICALS, INC. Warrant Shares: [ ] Issue Date: April 6, 2026 THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Dat |
|
| April 6, 2026 |
PRE-FUNDED COMMON STOCK PURCHASE WARRANT INOVIO PHARMACEUTICALS, INC. EX-4.1 Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT INOVIO PHARMACEUTICALS, INC. Warrant Shares: Date of Issuance: April 6, 2026 (such date, the “Issue Date”) Warrant No.: PF-[ ] THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, the registered holder hereof or its permitted assigns (the “Holder”) is entitled, upon the terms and subject to the limitat |
|
| April 6, 2026 |
EX-1.1 Exhibit 1.1 Execution Version INOVIO PHARMACEUTICALS, INC. (a Delaware corporation) 12,500,000 Shares of Common Stock Series A Warrants to Purchase Up to 12,500,000 Shares of Common Stock (or Pre-Funded Warrants in lieu thereof) Series B Warrants to Purchase Up to 12,500,000 Shares of Common Stock (or Pre-Funded Warrants in lieu thereof) UNDERWRITING AGREEMENT Dated: April 2, 2026 INOVIO PH |
|
| April 6, 2026 |
INOVIO Announces Pricing of $17.5 Million Public Offering EX-99.2 Exhibit 99.2 INOVIO Announces Pricing of $17.5 Million Public Offering PLYMOUTH MEETING, PA – April 2, 2026 /PRNewswire/ – INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten publi |
|
| April 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2026 Inovio Pharmaceuticals, Inc. |
|
| April 2, 2026 |
Subject to Completion, dated April 1, 2026 424B5 Table of Contents The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| April 2, 2026 |
Sole Manager Piper Sandler The date of this prospectus supplement is April 2, 2026. 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Number 333-275445 PROSPECTUS SUPPLEMENT (To Prospectus Dated January 31, 2024) 12,500,000 Shares of Common Stock Series A Warrants to Purchase up to 12,500,000 Shares of Common Stock (or Pre-Funded Warrants) Series B Warrants to Purchase up to 12,500,000 Shares of Common Stock (or Pre-Funded Warrants) We are offering 12,500,000 shares of our common stock, par value $0. |
|
| April 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2026 Inovio Pharmaceuticals, Inc. |
|
| March 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2026 Inovio Pharmaceuticals, Inc. |
|
| March 12, 2026 |
INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights Exhibit 99.1 INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights •Biologics License Application (BLA) for INO-3107 accepted for review under the Accelerated Approval Program as a potential treatment for adults with Recurrent Respiratory Papillomatosis (RRP) by the U.S. Food and Drug Administration (FDA); target Prescription Drug User Fee Act (PDUFA) da |
|
| March 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, INC. |
|
| January 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2026 Inovio Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-14888 33-0969592 (State or other jurisdiction of incorporation) (Comm |
|
| January 27, 2026 |
424B5 Filed Pursuant to Rule 424(b)(5) Registration File No. 333-275445 AMENDMENT NO. 1 TO PROSPECTUS SUPPLEMENT DATED JULY 2, 2025 (To Prospectus Dated January 31, 2024) 14,285,715 Shares of Common Stock Series A Warrants to Purchase up to 14,285,715 Shares of Common Stock (or Pre-Funded Warrants) Series B Warrants to Purchase up to 14,285,715 Shares of Common Stock (or Pre-Funded Warrants) This |
|
| January 27, 2026 |
AMENDMENT TO WARRANT TO PURCHASE COMMON STOCK INOVIO PHARMACEUTICALS, INC. EX-4.1 Exhibit 4.1 AMENDMENT TO WARRANT TO PURCHASE COMMON STOCK INOVIO PHARMACEUTICALS, INC. THIS AMENDMENT TO THE WARRANT TO PURCHASE COMMON STOCK, dated January 27, 2026 (“Amendment”), amends that certain Series A Warrant, dated as of July 7, 2025 (the “Series A Warrant”), issued by Inovio Pharmaceuticals, Inc., a Delaware corporation (the “Company”) for the benefit of [] or its assigns (the “H |
|
| December 29, 2025 |
EX-99.1 Exhibit 99.1 FDA Accepts for Review INOVIO’s BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP) PLYMOUTH MEETING, PA., December 29, 2025 /PRNewswire/ — INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, tod |
|
| December 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2025 Inovio Pharmaceuticals, Inc. |
|
| November 12, 2025 |
INOVIO Announces Proposed Public Offering EX-99.1 Exhibit 99.1 INOVIO Announces Proposed Public Offering PLYMOUTH MEETING, PA – November 10, 2025 /PRNewswire/ – INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it intends to offer and sell shares of its |
|
| November 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2025 Inovio Pharmaceuticals, Inc. |
|
| November 12, 2025 |
EX-1.1 Exhibit 1.1 Execution Version INOVIO PHARMACEUTICALS, INC. (a Delaware corporation) 13,158,000 Shares of Common Stock UNDERWRITING AGREEMENT Dated: November 11, 2025 INOVIO PHARMACEUTICALS, INC. (a Delaware corporation) 13,158,000 Shares of Common Stock UNDERWRITING AGREEMENT November 11, 2025 PIPER SANDLER & CO. as Representative of the several Underwriters c/o Piper Sandler & Co. 1251 Ave |
|
| November 12, 2025 |
Bookrunning Manager Piper Sandler The date of this prospectus supplement is November 11, 2025. 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Number 333-275445 PRELIMINARY PROSPECTUS SUPPLEMENT (To Prospectus Dated January 31, 2024) 13,158,000 Shares INOVIO PHARMACEUTICALS, INC. |
|
| November 12, 2025 |
Subject to Completion, dated November 10, 2025 424B5 Table of Contents The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| November 12, 2025 |
INOVIO Announces Pricing of $25 Million Public Offering EX-99.2 Exhibit 99.2 INOVIO Announces Pricing of $25 Million Public Offering PLYMOUTH MEETING, PA – November 11, 2025 /PRNewswire/ – INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten pub |
|
| November 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICA |
|
| November 10, 2025 |
INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights Exhibit 99.1 INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights •Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review •Expect to receive file acceptance by year end 2025 with potential PDUFA date in mid-2026 if request for priority review granted •Commercial preparations |
|
| November 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2025 Inovio Pharmaceuticals, Inc. |
|
| August 12, 2025 |
INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights Exhibit 99.1 INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights •On track to submit Biologics License Application (BLA) for INO-3107 in 2H25, with the goal of file acceptance by year end •Completed design verification (DV) testing of CELLECTRA® 5PSP device required for BLA submission and requested rolling submission from US Food and Drug Administration (FDA) •Conti |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, I |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 Inovio Pharmaceuticals, Inc. |
|
| August 12, 2025 |
Inovio Pharmaceuticals, Inc. Amended and Restated 2023 Omnibus Incentive Plan Exhibit 10.1 INOVIO PHARMACEUTICALS, INC. AMENDED AND RESTATED 2023 OMNIBUS INCENTIVE PLAN Adopted by the Board of Directors: February 27, 2025 Approved by Stockholders: May 20, 2025 Inovio Pharmaceuticals, Inc. Amended and Restated 2023 Omnibus Incentive Plan 1.General. (a)Prior Plan. The Company originally adopted the Inovio Pharmaceuticals, Inc. 2023 Omnibus Incentive Plan effective as of the O |
|
| July 7, 2025 |
EX-1.1 Exhibit 1.1 INOVIO PHARMACEUTICALS, INC. (a Delaware corporation) 14,285,715 Shares of Common Stock Series A Warrants to Purchase Up to 14,285,715 Shares of Common Stock (or Pre-Funded Warrants in lieu thereof) Series B Warrants to Purchase Up to 14,285,715 Shares of Common Stock (or Pre-Funded Warrants in lieu thereof) UNDERWRITING AGREEMENT Dated: July 2, 2025 INOVIO PHARMACEUTICALS, INC. |
|
| July 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2025 Inovio Pharmaceuticals, Inc. |
|
| July 7, 2025 |
EX-4.3 Exhibit 4.3 WARRANT TO PURCHASE COMMON STOCK INOVIO PHARMACEUTICALS, INC. Warrant Shares: [ ] Issue Date: July 7, 2025 THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date |
|
| July 7, 2025 |
EX-4.1 Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT INOVIO PHARMACEUTICALS, INC. Warrant Shares: Date of Issuance: July 7, 2025 (such date, the “Issue Date”) Warrant No.: PF-[ ] THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, the registered holder hereof or its permitted assigns (the “Holder”) is entitled, upon the terms and subject to the limitati |
|
| July 7, 2025 |
INOVIO Announces Pricing of $25 Million Public Offering Exhibit 99.2 INOVIO Announces Pricing of $25 Million Public Offering PLYMOUTH MEETING, PA – July 2, 2025 /PRNewswire/ – INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering |
|
| July 7, 2025 |
EX-4.2 Exhibit 4.2 WARRANT TO PURCHASE COMMON STOCK INOVIO PHARMACEUTICALS, INC. Warrant Shares: [ ] Issue Date: July 7, 2025 THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Dat |
|
| July 7, 2025 |
INOVIO Announces Proposed Public Offering EX-99.1 Exhibit 99.1 INOVIO Announces Proposed Public Offering PLYMOUTH MEETING, PA – July 2, 2025 /PRNewswire/ – INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it intends to offer and sell shares of its commo |
|
| July 3, 2025 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Number 333-275445 PROSPECTUS SUPPLEMENT (To Prospectus Dated January 31, 2024) 14,285,715 Shares of Common Stock Series A Warrants to Purchase up to 14,285,715 Shares of Common Stock (or Pre-Funded Warrants) Series B Warrants to Purchase up to 14,285,715 Shares of Common Stock (or Pre-Funded Warrants) We are offering 14,285,715 shares of our common stock, par value $0. |
|
| July 2, 2025 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Number 333-275445 The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2025 Inovio Pharmaceuticals, Inc. |
|
| May 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 Inovio Pharmaceuticals, Inc. |
|
| May 13, 2025 |
INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights Exhibit 99.1 INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights •On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) in mid-2025 ◦Device design verification (DV) testing of CELLECTRA device required for BLA submission is underway, anticipated completion in 1H |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, |
|
| April 7, 2025 |
Dr. Jacqueline Shea, President and CEO As we reflect on 2024 and look ahead to 2025, I am very pleased to share some highlights of the considerable progress INOVIO has made and our plans for the potentially transformational year that lies ahead. We are on the cusp of bringing our first product candidate to market, which would also be the first DNA medicine available in the US. Our aim is to enable |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| March 18, 2025 |
Subsidiaries of the registrant (filed herewith). Exhibit 21.1 INOVIO PHARMACEUTICALS, INC. Subsidiaries Subsidiary Name(1) Jurisdiction of Organization Inovio Asia, LLC South Korea |
|
| March 18, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 Inovio Pharmaceuticals, Inc. |
|
| March 18, 2025 |
INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights Exhibit 99.1 INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights •Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) –Resolved previously announced manufacturing issue concerning the single-use array component of the CELLECTRA device and completed |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, INC. |
|
| March 18, 2025 |
Insider Trading Policy (filed herewith) Exhibit 19.1 Insider Trading Policy Amended and Restated on May 16, 2023 MEMORANDUM TO: All Company Personnel FROM: Inovio Pharmaceuticals, Inc. DATE: May 16, 2023 (Amended and Restated) RE: Compliance with the Company’s Insider Trading Policy As a director, officer, employee, consultant or contractor of Inovio Pharmaceuticals, Inc., a Delaware corporation (the “Company”), your ability to purchase |
|
| February 5, 2025 |
EX-24 2 PowerOfAttorney.txt EXHIBIT 24: POWER OF ATTORNEY POWER OF ATTORNEY The undersigned, BlackRock, Inc., a corporation duly organized under the laws of the State of Delaware, United States (the "Company"), does hereby make, constitute and appoint each of Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Laura Hildner, David Maryles, Christopher Meade, Charles Park, Jam |
|
| February 5, 2025 |
EX-99 3 ITEM7.txt EXHIBIT 99: ITEM 7 BlackRock Advisors, LLC SpiderRock Advisors, LLC BlackRock Fund Advisors BlackRock Institutional Trust Company, National Association BlackRock Financial Management, Inc. BlackRock Investment Management, LLC *Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. |
|
| December 23, 2024 |
AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G EXHIBIT 99 AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5(and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. |
|
| December 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2024 Inovio Pharmaceuticals, Inc. |
|
| December 16, 2024 |
Exhibit 4.1 WARRANT TO PURCHASE COMMON STOCK INOVIO PHARMACEUTICALS, INC. Warrant Shares: [ ] Issue Date: December 16, 2024 THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the I |
|
| December 16, 2024 |
Exhibit 1.1 INOVIO PHARMACEUTICALS, INC. (a Delaware corporation) 10,000,000 Shares of Common Stock Warrants to Purchase Up to 10,000,000 Shares of Common Stock UNDERWRITING AGREEMENT Dated: December 12, 2024 INOVIO PHARMACEUTICALS, INC. (a Delaware corporation) 10,000,000 Shares of Common Stock Warrants to Purchase Up to 10,000,000 Shares of Common Stock UNDERWRITING AGREEMENT December 12, 2024 O |
|
| December 16, 2024 |
INOVIO Announces Pricing of $30 Million Public Offering Exhibit 99.1 INOVIO Announces Pricing of $30 Million Public Offering PLYMOUTH MEETING, PA – December 13, 2024 /PRNewswire/ – INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offe |
|
| December 13, 2024 |
10,000,000 shares of common stock Warrants to purchase 10,000,000 shares of common stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Number 333-275445 PROSPECTUS SUPPLEMENT (To Prospectus Dated January 31, 2024) 10,000,000 shares of common stock Warrants to purchase 10,000,000 shares of common stock We are offering 10,000,000 shares of our common stock, par value $0. |
|
| December 12, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Number 333-275445 The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| November 14, 2024 |
INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights Exhibit 99.1 INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights –New immunology data for INO-3107 supporting proposed mechanism of action presented at several recent conferences •Data showed ability of INO-3107 to induce an antigen-specific cytotoxic T cell response against HPV-6 and HPV-11 and drive recruitment of T cells into airway tissues and papilloma •Data sho |
|
| November 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 Inovio Pharmaceuticals, Inc. |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICA |
|
| November 8, 2024 |
INO / Inovio Pharmaceuticals, Inc. / BlackRock, Inc. Passive Investment SC 13G 1 us45773h4092110824.txt us45773h4092110824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) INOVIO PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 45773H409 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| October 22, 2024 |
INO / Inovio Pharmaceuticals, Inc. / BlackRock, Inc. Passive Investment SC 13G 1 us45773h4092102224.txt us45773h4092102224.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) INOVIO PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 45773H409 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| August 13, 2024 |
Exhibit 1.1 Inovio Pharmaceuticals, Inc. Common Stock, $0.001 par value EQUITY DISTRIBUTION AGREEMENT August 13, 2024 Oppenheimer & Co. Inc. 85 Broad Street New York, New York 10004 Ladies and Gentlemen: Inovio Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Oppenheimer & Co. Inc |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 Inovio Pharmaceuticals, Inc. |
|
| August 13, 2024 |
Up to $60,000,000 Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Number 333-275445 PROSPECTUS SUPPLEMENT (To Prospectus Dated January 31, 2024) Up to $60,000,000 Common Stock We have entered into an Equity Distribution Agreement, or the Sales Agreement, with Oppenheimer & Co. |
|
| August 8, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 Inovio Pharmaceuticals, Inc. |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, I |
|
| August 8, 2024 |
INOVIO Reports Second Quarter 2024 Financial Results and Recent Business Highlights Exhibit 99.1 INOVIO Reports Second Quarter 2024 Financial Results and Recent Business Highlights PLYMOUTH MEETING, PA – August 8, 2024 – INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the second quarter of 2024 |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2024 Inovio Pharmaceuticals, Inc. |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, |
|
| May 13, 2024 |
INOVIO Reports First Quarter 2024 Financial Results and Recent Business Highlights Exhibit 99.1 INOVIO Reports First Quarter 2024 Financial Results and Recent Business Highlights • BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgical treatment for recurrent respiratory papillomatosis (RRP) • Planning initiation of confirmatory trial for INO-3107 based on FDA feedback • Advancing plans for Phase 3 |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 Inovio Pharmaceuticals, Inc. |
|
| April 26, 2024 |
INO / Inovio Pharmaceuticals, Inc. / Deep Track Capital, LP Passive Investment SC 13G 1 deeptrack-ino041624.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* INOVIO PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 45773H409 (CUSIP Number) April 16, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| April 17, 2024 |
Exhibit 1.1 INOVIO PHARMACEUTICALS, INC. (a Delaware corporation) 2,536,258 Shares of Common Stock Pre-Funded Warrants to Purchase Up to 2,135,477 Shares of Common Stock UNDERWRITING AGREEMENT Dated: April 15, 2024 INOVIO PHARMACEUTICALS, INC. (a Delaware corporation) 2,536,258 Shares of Common Stock Pre-Funded Warrants to Purchase Up to 2,135,477 Shares of Common Stock UNDERWRITING AGREEMENT Apri |
|
| April 17, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Number 333-275445 PROSPECTUS SUPPLEMENT (To Prospectus Dated January 31, 2024) 2,536,258 shares of common stock Pre-funded warrants to purchase up to 2,135,477 shares of common stock We are offering 2,536,258 shares of our common stock, par value $0. |
|
| April 17, 2024 |
EX-99.1 Exhibit 99.1 INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants PLYMOUTH MEETING, Pa., April 15, 2024 /PRNewswire/ — INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious dis |
|
| April 17, 2024 |
EX-4.1 Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT INOVIO PHARMACEUTICALS, INC. Warrant Shares: Date of Issuance: , 2024 (such date, the “Issue Date”) Warrant No.: PF-[ ] THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, the registered holder hereof or its permitted assigns (the “Holder”) is entitled, upon the terms and subject to the limitat |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2024 Inovio Pharmaceuticals, Inc. |
|
| April 15, 2024 |
INOVIO POWERING DNA MEDICINES ™ 660 W. Germantown Pike, Suite 110, Plymouth Meeting, PA 19462 Phone:267-440-4200 Fax:267-440-4242 www.inovio.com Dear Shareholder, The past year has been transformational for INOVIO. Today we are a company planning to submit a Biologics License Application (BLA) for our lead product candidate, INO-3107, in the second half of 2024 under the FDA’s accelerated approval |
|
| April 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| March 6, 2024 |
Participation Agreement under Severance Plan for Laurent Humeau (filed herewith). Exhibit 10.19 Appendix A INOVIO PHARMACEUTICALS, INC. SEVERANCE PLAN Participation Agreement Inovio Pharmaceuticals, Inc. (the “Company”) is pleased to inform you, Laurent M. Humeau, that you have been selected to participate in the Company’s Severance Plan (the “Plan”) as a Covered Employee. A copy of the Plan was delivered to you with this Participation Agreement. Your participation in the Plan |
|
| March 6, 2024 |
Participation Agreement under Severance Plan for Michael Sumner (filed herewith). Exhibit 10.20 Appendix A INOVIO PHARMACEUTICALS, INC. SEVERANCE PLAN Participation Agreement Inovio Pharmaceuticals, Inc. (the “Company”) is pleased to inform you, Michael Sumner, that you have been selected to participate in the Company’s Severance Plan (the “Plan”) as a Covered Employee. A copy of the Plan was delivered to you with this Participation Agreement. Your participation in the Plan is |
|
| March 6, 2024 |
Participation Agreement under Severance Plan for Jacqueline Shea (filed herewith). Exhibit 10.18 Appendix A INOVIO PHARMACEUTICALS, INC. SEVERANCE PLAN Participation Agreement Inovio Pharmaceuticals, Inc. (the “Company”) is pleased to inform you, Jacqueline E. Shea, that you have been selected to participate in the Company’s Severance Plan (the “Plan”) as a Covered Employee. A copy of the Plan was delivered to you with this Participation Agreement. Your participation in the Plan |
|
| March 6, 2024 |
Subsidiaries of the registrant (filed herewith). Exhibit 21.1 INOVIO PHARMACEUTICALS, INC. Subsidiaries Subsidiary Name(1) Jurisdiction of Organization Inovio Asia, LLC South Korea |
|
| March 6, 2024 |
Exhibit 10.11 FIRST AMENDMENT TO THE AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT This First Amendment to the Amended and Restated License and Collaboration Agreement (this “First Amendment”), dated as of June 14, 2023 (the “First Amendment Date”), is entered into by and between Beijing Apollo Saturn Biological Technology Limited, a People’s Republic of China corporation having a princ |
|
| March 6, 2024 |
Inovio Pharmaceuticals, Inc. Severance Plan and Summary Plan Description (filed herewith). Exhibit 10.17 INOVIO PHARMACEUTICALS, INC. SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION APPROVED BY THE BOARD OF DIRECTORS: 1.Introduction. The purpose of this Inovio Pharmaceuticals, Inc. Severance Plan (the “Plan”) is to provide specified severance benefits to eligible executives of the Company (as defined below) whose employment is terminated by the Company or a successor under certain circumsta |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, INC. |
|
| March 6, 2024 |
Incentive Compensation Recoupment Policy, adopted on November 14, 2023 (filed herewith) Exhibit 97.1 INOVIO PHARMACEUTICALS, INC. Incentive Compensation Recoupment Policy 1.Introduction The Board of Directors (the “Board”) of Inovio Pharmaceuticals, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the Company’s recoupmen |
|
| February 13, 2024 |
INO / Inovio Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01190-inoviopharmaceutical.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Inovio Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 45773H201 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box |
|
| January 29, 2024 |
January 29, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N. |
|
| January 26, 2024 |
As filed with the Securities and Exchange Commission on January 26, 2024 As filed with the Securities and Exchange Commission on January 26, 2024 Registration No. |
|
| January 26, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Inovio Pharmaceuticals, Inc. |
|
| January 25, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF INOVIO PHARMACEUTICALS, INC. Inovio Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Company”), hereby certifies that: FIRST: The name of this Company is Inovio Pharmaceuticals, Inc. SECOND: The original name of the Company was “Ge |
|
| January 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2024 Inovio Pharmaceuticals, Inc. |
|
| January 22, 2024 |
INO / Inovio Pharmaceuticals, Inc. / STATE STREET CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 EXIT FILING INOVIO PHARMACEUTICALS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 45773H201 (CUSIP NUMBER) 12/31/2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE I |
|
| January 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2024 Inovio Pharmaceuticals, Inc. |
|
| November 28, 2023 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 17, 2023 |
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 16, 2023 |
United States securities and exchange commission logo November 16, 2023 Jacqueline Shea President and Chief Executive Officer Inovio Pharmaceuticals, Inc. |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 Inovio Pharmaceuticals, Inc. |
|
| November 9, 2023 |
INOVIO Reports Third Quarter 2023 Financial Results and Operational Highlights Exhibit 99.1 INOVIO Reports Third Quarter 2023 Financial Results and Operational Highlights • Achieved significant progress with lead product candidate, INO-3107 • Received Breakthrough Therapy designation from U.S. Food and Drug Administration (FDA) as a potential treatment for Recurrent Respiratory Papillomatosis (RRP) • Received FDA feedback that data from completed Phase 1/2 trial could be use |
|
| November 9, 2023 |
Form of Indenture, between the registrant and one or more trustees to be named. Exhibit 4.5 INOVIO PHARMACEUTICALS, INC, Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate |
|
| November 9, 2023 |
As filed with the Securities and Exchange Commission on November 9, 2023 Table of Contents As filed with the Securities and Exchange Commission on November 9, 2023 Registration No. |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICA |
|
| November 9, 2023 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.9 INOVIO PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF INOVIO PHARMACEUTICALS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between INOVIO PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] o |
|
| November 9, 2023 |
Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.7 INOVIO PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF INOVIO PHARMACEUTICALS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between INOVIO PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized |
|
| November 9, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Inovio Pharmaceuticals, Inc. |
|
| November 9, 2023 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.8 INOVIO PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF INOVIO PHARMACEUTICALS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between INOVIO PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] o |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 Inovio Pharmaceuticals, Inc. |
|
| October 10, 2023 |
Regulation FD Disclosure, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2023 Inovio Pharmaceuticals, Inc. |
|
| October 10, 2023 |
EX-99.1 Exhibit 99.1 INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA Under Accelerated Approval Program – Previously planned Phase 3 trial no longer required to support Biological License Application (BLA) submission – If approved, INO-3107 could potentially revolutionize treatment options for patients with Recurrent Respiratory Papillo |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 Inovio Pharmaceuticals, Inc. |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, I |
|
| August 9, 2023 |
Exhibit 10.3 Inovio Pharmaceuticals, Inc. RSU Award Grant Notice (2023 Omnibus Incentive Plan) Inovio Pharmaceuticals, Inc. (the “Company”) has awarded to you (the “Participant”) the number of restricted stock units specified and on the terms set forth below (the “RSU Award”). Your RSU Award is subject to all of the terms and conditions as set forth herein and in the Company’s 2023 Omnibus Incenti |
|
| August 9, 2023 |
Exhibit 99.1 INOVIO Announces Second Quarter 2023 Financial Results and Provides Strategic Update Preparing to initiate pivotal Phase 3 trial of INO-3107 in adult RRP patients in first quarter of 2024; INO-3107 received Orphan Drug Designation from European Commission in second quarter Scaling resources and headcount to align with strategic focus on INO-3107 and late-stage clinical candidates clos |
|
| August 9, 2023 |
Exhibit 10.2 Inovio Pharmaceuticals, Inc. Stock Option Grant Notice (2023 Omnibus Incentive Plan) Inovio Pharmaceuticals, Inc. (the “Company”) (the “Company”), pursuant to the Company’s 2023 Omnibus Incentive Plan (the “Plan”), has granted to you (“You,” or “Optionholder”) an option to purchase the number of shares of the Common Stock set forth below (the “Option”). Your Option is subject to all o |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 Inovio Pharmaceuticals, Inc. |
|
| July 10, 2023 |
INO / Inovio Pharmaceuticals Inc / STATE STREET CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 EXIT FILING INOVIO PHARMACEUTICALS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 45773H201 (CUSIP NUMBER) 06/30/2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE I |
|
| July 7, 2023 |
INO / Inovio Pharmaceuticals Inc / BlackRock Inc. Passive Investment us45773h2013070723.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 9) INOVIO PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 45773H201 - (CUSIP Number) June 30, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2023 Inovio Pharmaceuticals, Inc. |
|
| June 23, 2023 |
EX-99.2 Exhibit 99.2 INOVIO Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions PLYMOUTH MEETING, PA., June 23, 2023 — INOVIO (NASDAQ: INO) has released the following pursuant to an order of the UNITED STATES DISTRICT COURT EASTERN DISTRICT OF PENNSYLVANIA: UNITED STATES DISTRICT COURT EASTERN DISTRICT OF PENNSYLVANIA IN RE INOVIO PHARMACEUTICALS, INC. DERIVATIVE |
|
| June 23, 2023 |
EX-99.1 Exhibit 99.1 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF PENNSYLVANIA IN RE INOVIO PHARMACEUTICALS, INC. DERIVATIVE LITIGATION Lead Case No. 2:20-cv-01962-GJP STIPULATION AND AGREEMENT OF SETTLEMENT This Stipulation and Agreement of Settlement (the “Stipulation”) is made and entered into by the following parties, each by and through their respective counsel: (1) plaintiffs Pedram Behe |
|
| May 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 Inovio Pharmaceuticals, Inc. |
|
| May 18, 2023 |
As filed with the Securities and Exchange Commission on May 18, 2023 S-8 As filed with the Securities and Exchange Commission on May 18, 2023 Registration No. |
|
| May 18, 2023 |
EX-10.1 Exhibit 10.1 INOVIO PHARMACEUTICALS, INC. 2023 OMNIBUS INCENTIVE PLAN Adopted by the Board of Directors: March 24, 2023 Approved by Stockholders: May 16, 2023 INOVIO PHARMACEUTICALS, INC. 2023 OMNIBUS INCENTIVE PLAN 1. GENERAL. (a) Prior Plan. As of May 16, 2023, no additional awards may be granted under the Prior Plan. All awards granted under the Prior Plan will remain subject to the ter |
|
| May 18, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 INOVIO PHARMACEUTICALS, INC. |
|
| May 18, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 INOVIO PHARMACEUTICALS, INC. |
|
| May 18, 2023 |
As filed with the Securities and Exchange Commission on May 18, 2023 S-8 As filed with the Securities and Exchange Commission on May 18, 2023 Registration No. |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 Inovio Pharmaceuticals, Inc. |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, |
|
| May 10, 2023 |
INOVIO Reports First Quarter 2023 Financial Results and Operational Highlights EX-99.1 Exhibit 99.1 INOVIO Reports First Quarter 2023 Financial Results and Operational Highlights • Announced additional positive data from Phase 1/2 trial for INO-3107 in recurrent respiratory papillomatosis patients • Second cohort of trial showed 10 of the 11 (91%) patients saw a reduction in surgical interventions in the year following initial treatment • New combined safety and immunologica |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| March 28, 2023 |
As filed with the Securities and Exchange Commission on March 28, 2023 POS EX As filed with the Securities and Exchange Commission on March 28, 2023 Registration No. |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| March 28, 2023 |
Dear Shareholder, In my first letter to you as President and CEO, let me begin by expressing how excited I am to lead INOVIO into its next chapter. |
|
| March 1, 2023 |
INOVIO Reports Fourth Quarter and Full Year 2022 Financial Results and Clinical Highlights EX-99.1 Exhibit 99.1 INOVIO Reports Fourth Quarter and Full Year 2022 Financial Results and Clinical Highlights • Announces topline results from REVEAL2, the second Phase 3 trial evaluating VGX-3100 as a treatment for cervical high-grade squamous intraepithelial lesions (HSIL) • Trial results did not meet the primary endpoint in the biomarker-selected population • Trial results did achieve statist |
|
| March 1, 2023 |
As filed with the Securities and Exchange Commission on March 1, 2023 POSASR Table of Contents As filed with the Securities and Exchange Commission on March 1, 2023 Registration No. |
|
| March 1, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Post-Effective Amendment to Form S-3 (Form Type) Inovio Pharmaceuticals, Inc. |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2023 Inovio Pharmaceuticals, Inc. |
|
| March 1, 2023 |
As filed with the Securities and Exchange Commission on March 1, 2023 POS AM As filed with the Securities and Exchange Commission on March 1, 2023 Registration No. |
|
| March 1, 2023 |
Subsidiaries of the registrant (filed herewith). Exhibit 21.1 INOVIO PHARMACEUTICALS, INC. Subsidiaries Subsidiary Name(1) Jurisdiction of Organization Inovio Asia, LLC South Korea |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, INC. |
|
| February 9, 2023 |
INO / Inovio Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01150-inoviopharmaceutical.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Inovio Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 45773H201 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate bo |
|
| February 9, 2023 |
INO / Inovio Pharmaceuticals Inc / STATE STREET CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 AMEMDED FILING INOVIO PHARMACEUTICALS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 45773H201 (CUSIP NUMBER) 12/31/2022 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDUL |
|
| January 31, 2023 |
EX-99.1 Exhibit 99.1 INOVIO Announces Strategic Reorganization, Continues Efforts to Focus on Promising DNA Medicine Candidates • Cost-saving measures include 11% headcount reduction • Annual savings expected to be approximately $4.3 million • Data readouts expected in first quarter of 2023 for key programs including INO-3107 for RRP and VGX-3100 for cervical HSIL PLYMOUTH MEETING, PA, January 31, |
|
| January 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2023 Inovio Pharmaceuticals, Inc. |
|
| January 24, 2023 |
INO / Inovio Pharmaceuticals Inc / BlackRock Inc. Passive Investment SC 13G/A 1 us45773h2013012423.txt us45773h2013012423.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 8) INOVIO PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 45773H201 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropr |
|
| November 8, 2022 |
EX-99.1 Exhibit 99.1 INOVIO Reports Financial Results and Highlights for the Third Quarter 2022 • Announced positive interim data for INO-3107 as a potential first-in-class treatment for Recurrent Respiratory Papillomatosis • Advanced strategy to focus on developing candidates that have the greatest opportunity for near-term success • Updates prior financial guidance and extends cash runway into f |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICA |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 Inovio Pharmaceuticals, Inc. |
|
| October 14, 2022 |
United States securities and exchange commission logo October 14, 2022 Peter Kies Chief Financial Officer Inovio Pharmaceuticals, Inc. |
|
| September 29, 2022 |
Brian F. Leaf T: +1 703 456 8053 [email protected] VIA EDGAR September 29, 2022 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Attn: Jenn Do Christine Torney Re: Inovio Pharmaceuticals, Inc. Form 10-K for the fiscal year ended December 31, 2021 Filed March 1, 2022 File No. 001-14888 Dear Ms. Do and Ms. Torney: |
|
| September 15, 2022 |
United States securities and exchange commission logo September 15, 2022 Peter Kies Chief Financial Officer Inovio Pharmaceuticals, Inc. |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 Inovio Pharmaceuticals, Inc. |
|
| August 9, 2022 |
INOVIO Reports Financial Results and Highlights for the Second Quarter 2022 Exhibit 99.1 INOVIO Reports Financial Results and Highlights for the Second Quarter 2022 ? Increased Cash Runway into Third Quarter 2024 with Cost-Savings and Corporate Restructuring Efforts ? Strengthened Executive Team with Appointment of Dr. Michael Sumner as Chief Medical Officer ? Announced Positive Data from a Phase 1/2 Trial with INO-5401 to treat Glioblastoma (GBM) at the American Society |
|
| August 9, 2022 |
Exhibit 10.1 May 9, 2022 Dr. J. Joseph Kim Re: Separation Agreement Dear Joseph: This letter sets forth the substance of the separation agreement (the ?Agreement?) which Inovio Pharmaceuticals, Inc. (the ?Company?) and you have agreed to in connection with your cessation of employment. 1.Separation. You and the Company have mutually agreed that your employment with the Company will end on May 10, |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, I |
|
| July 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2022 Inovio Pharmaceuticals, Inc. |
|
| July 19, 2022 |
Exhibit 99.1 INOVIO Announces Corporate Reorganization to Reduce Operational Expenses and Focus on Opportunities to Bring the Promise of DNA Medicines to Patients ? Changes expected to reduce operational expenses and extend the company?s cash runway into third quarter of 2024 ? Improving cost structure will allow company to focus on strategic priorities, including heterologous boost strategy for C |
|
| June 30, 2022 |
Exhibit 99.2 INOVIO PHARMACEUTICALS, INC. STOCK OPTION GRANT NOTICE (2022 INDUCEMENT PLAN) Inovio Pharmaceuticals, Inc. (the ?Company?) (the ?Company?), pursuant to the Company?s 2022 Inducement Plan (the ?Plan?), has granted to you (?You,? or ?Optionholder?) an option to purchase the number of shares of the Common Stock set forth below (the ?Option?). Your Option is subject to all of the terms an |
|
| June 30, 2022 |
Powers of Attorney (included on signature page). As filed with the Securities and Exchange Commission on June 30, 2022 Registration No. |
|
| June 30, 2022 |
Exhibit 99.3 INOVIO PHARMACEUTICALS, INC. RSU AWARD GRANT NOTICE (2022 INDUCEMENT PLAN) Inovio Pharmaceuticals, Inc. (the ?Company?) has awarded to you (the ?Participant?) the number of restricted stock units specified and on the terms set forth below (the ?RSU Award?). Your RSU Award is subject to all of the terms and conditions as set forth herein and in the Company?s 2022 Inducement Plan (the ? |
|
| June 30, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 INOVIO PHARMACEUTICALS, INC. |
|
| June 30, 2022 |
Exhibit 99.1 INOVIO PHARMACEUTICALS, INC. 2022 INDUCEMENT PLAN ADOPTED BY THE BOARD OF DIRECTORS: JUNE 24, 2022 TABLE OF CONTENTS Page 1. GENERAL. 1 2. SHARES SUBJECT TO THE PLAN. 1 3. ELIGIBILITY AND LIMITATIONS. 2 4. OPTIONS AND STOCK APPRECIATION RIGHTS. 2 5. AWARDS OTHER THAN OPTIONS AND STOCK APPRECIATION RIGHTS. 6 6. ADJUSTMENTS UPON CHANGES IN COMMON STOCK; OTHER CORPORATE EVENTS. 8 7. ADMI |
|
| May 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 Inovio Pharmaceuticals, Inc. |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, |
|
| May 10, 2022 |
Exhibit 99.2 INOVIO Announces the Appointment of Jacqueline Shea, Ph.D., as Chief Executive Officer Dr. Shea brings more than 25 years of leadership and industry expertise in life sciences and biotech PLYMOUTH MEETING, PA ? May 10, 2022 ? INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat pe |
|
| May 10, 2022 |
INOVIO Reports First Quarter 2022 Financial Results and Program Developments Exhibit 99.1 INOVIO Reports First Quarter 2022 Financial Results and Program Developments ? Announces prioritization of heterologous booster strategy for COVID-19 vaccine candidate INO-4800 and discontinuation of Phase 3 INNOVATE trial to optimize potential impact on global public health ? Reports, with partner Advaccine, positive T cell immune response data with INO-4800 as a heterologous booster |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 Inovio Pharmaceuticals, Inc. |
|
| April 11, 2022 |
INO / Inovio Pharmaceuticals Inc / STATE STREET CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 AMENDED FILING INOVIO PHARMACEUTICALS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 45773H201 (CUSIP NUMBER) 03/31/2022 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDUL |
|
| March 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| March 1, 2022 |
Subsidiaries of the registrant (filed herewith). EX-21.1 2 ino-12312021x10kex211.htm EX-21.1 Exhibit 21.1 INOVIO PHARMACEUTICALS, INC. Subsidiaries Subsidiary Name(1) Jurisdiction of Organization Inovio Asia, LLC South Korea |
|
| March 1, 2022 |
As filed with the Securities and Exchange Commission on March 1, 2022 As filed with the Securities and Exchange Commission on March 1, 2022 Registration No. |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, INC. |
|
| March 1, 2022 |
Resolutions adopted by the Board of Directors Ratifying Option Exhibit 99.1 Inovio Pharmaceuticals, Inc. Resolutions of the Board of Directors Ratification of Equity Awards Made By CEO Approved and adopted: February 24, 2022 Ratification of the Grant of Certain Stock Options and Restricted Stock Units WHEREAS, pursuant to Section 157(c) of the General Corporation Law of the State of Delaware ("DGCL"), a board of directors may, by a resolution, authorize an of |
|
| March 1, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 INOVIO PHARMACEUTICALS, INC. |
|
| February 11, 2022 |
INO / Inovio Pharmaceuticals Inc / STATE STREET CORP Passive Investment SC 13G/A 1 INOVIOPHARMACEUTICALSINC.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 AMENDED FILING INOVIO PHARMACEUTICALS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 45773H201 (CUSIP NUMBER) 12/31/2021 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE |
|
| February 10, 2022 |
INO / Inovio Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Inovio Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 45773H201 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 1, 2022 |
INO / Inovio Pharmaceuticals Inc / BlackRock Inc. Passive Investment us45773h2013020122.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 7) INOVIO PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 45773H201 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| November 9, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-252256 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be registered Maximum Offering Price Per Share Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, $0.001 par value (1) (1) $300,000,000 $27,810 (1) An indeterminate number of shares of common stock as s |
|
| November 9, 2021 |
Exhibit 10.1 EXECUTION VERSION Inovio Pharamceuticals, Inc. Common Stock, $0.001 par value ATM EQUITY OFFERINGSM SALES AGREEMENT November 9, 2021 BofA Securities, Inc. RBC Capital Markets, LLC Oppenheimer & Co. Inc. c/o BofA Securities, Inc. One Bryant Park New York, New York 10036 c/o RBC Capital Markets, LLC Brookfield Place 200 Vesey Street, 8th Floor New York, New York 10281 c/o Oppenheimer & |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICA |
|
| October 29, 2021 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2021 Inovio Pharmaceuticals, Inc. |
|
| October 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2021 Inovio Pharmaceuticals, Inc. |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, I |
|
| August 9, 2021 |
Exhibit 10.1 AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT This Amended and Restated Collaboration and License Agreement (the ?Agreement?) is entered into as of June 7, 2021 (the ?Effective Date?) by and between Inovio Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware and having a place of business at 60 W. Germantown Pike, Suite 110, Plymouth Meetin |
|
| June 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2021 Inovio Pharmaceuticals, Inc. |
|
| June 11, 2021 |
Exhibit 99.1 INOVIO Expands Partnership with Advaccine to Conduct Global Phase 3 Efficacy Trial of COVID-19 DNA Vaccine Candidate, INO-4800 Phase 3 efficacy trial planned to commence this summer in areas of the world underserved by vaccines News follows recently announced Phase 2 data, which showed INO-4800 to be well-tolerated and immunogenic in all age groups PLYMOUTH MEETING, Pa., June 8, 2021 |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 Inovio Pharmaceuticals, Inc. |
|
| May 17, 2021 |
Exhibit 99.1 INOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors Dr. Dansey, Seagen?s Chief Medical Officer, brings extensive expertise in immuno-oncology and drug development Appointment of industry leader in drug development expands the Board?s diverse industry, clinical development, research and commercialization expertise PLYMOUTH MEETING, PA ? May 17, 2021 ? INOVIO ( |
|
| May 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, |
|
| March 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| March 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, INC. |
|
| March 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2021 Inovio Pharmaceuticals, Inc. |
|
| March 1, 2021 |
INOVIO Reports Fourth Quarter 2020 And Year-End Financial Results Investor Call Today at 4:30 PM ET EX-99.1 Exhibit 99.1 INOVIO Reports Fourth Quarter 2020 And Year-End Financial Results Investor Call Today at 4:30 PM ET PLYMOUTH MEETING, PA – March 1, 2021 – INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today reported financial results |
|
| March 1, 2021 |
Subsidiaries of the registrant (filed herewith). Exhibit 21.1 INOVIO PHARMACEUTICALS, INC. Subsidiaries Subsidiary Name(1) Jurisdiction of Organization Inovio Asia, LLC South Korea |
|
| March 1, 2021 |
As filed with the Securities and Exchange Commission on March 1, 2021 Registration No. |
|
| March 1, 2021 |
Exhibit 99.2 INOVIO Announces Positive Results from REVEAL 1, a Phase 3 Pivotal Trial Evaluating VGX-3100, its DNA-based HPV Immunotherapy for the Treatment of High-grade Precancerous Cervical Dysplasia Caused by HPV-16 and/or HPV-18 Trial achieved primary and secondary efficacy endpoints among all evaluable subjects in the Phase 3 multi-center, randomized, double-blind, placebo-controlled trial. |
|
| March 1, 2021 |
Exhibit 10.14 EXECUTION COPY COLLABORATION AND LICENSE AGREEMENT This Collaboration and License Agreement (the ?Agreement?) is entered into as of December 31, 2020 (the ?Effective Date?) by and between Inovio Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware and having a place of business at 60 W. Germantown Pike, Suite 110, Plymouth Meeting, PA 19462 USA (?Ino |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Inovio Pharmaceuticals, Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 45773H201 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| February 11, 2021 |
SCHEDULE 13G Amendment No. 2 Name of Issuer: Inovio Pharmaceuticals, Inc. Title of Class of Securities: Common Stock CUSIP Number: 45773H201 Item 1: Reporting Person: Wasatch Advisors, Inc. 87-0319391 Item 2: Check Box If Member of Group: Not Applicable Item 3: SEC Use Item 4: Place of Organization: Utah Items 5-8: Number of Shares Owned With: Item 5: Sole Voting Power: 3,939,018 Item 6: Shared Vo |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Inovio Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 45773H201 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 ANNUAL FILING INOVIO PHARMACEUTICALS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 45773H201 (CUSIP NUMBER) 12/31/2020 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE |
|
| February 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Inovio Pharmaceuticals, Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 45773H201 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designat |
|
| January 29, 2021 |
us45773h2013012921.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 6) INOVIO PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 45773H201 - (CUSIP Number) December 31, 2020 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| January 22, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 20, 2021 Inovio Pharmaceuticals, Inc. |
|
| January 22, 2021 |
EX-1.1 Exhibit 1.1 Execution Version INOVIO PHARMACEUTICALS, INC. (a Delaware corporation) 17,700,000 Shares of Common Stock UNDERWRITING AGREEMENT Dated: January 20, 2021 INOVIO PHARMACEUTICALS, INC. (a Delaware corporation) 17,700,000 Shares of Common Stock UNDERWRITING AGREEMENT January 20, 2021 BofA Securities, Inc. Jefferies LLC as Representatives of the several Underwriters c/o BofA Securiti |
|
| January 22, 2021 |
INOVIO Announces Proposed Public Offering of Common Stock EX-99.1 Exhibit 99.1 INOVIO Announces Proposed Public Offering of Common Stock PLYMOUTH MEETING, Pa., January 20, 2021 (Globe Newswire) — INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated diseases, today announced that |
|
| January 22, 2021 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-252256 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be registered(1) Maximum Offering Price Per Share Maximum Aggregate Offering Price Amount of Registration Fee(2)(3) Common Stock, $0.001 par value 20,355,000 $8.50 $173,017,500.00 $18,876.21 (1) Assumes exercise in full of |
|
| January 22, 2021 |
INOVIO Announces Pricing of Public Offering of Common Stock EX-99.2 Exhibit 99.2 INOVIO Announces Pricing of Public Offering of Common Stock PLYMOUTH MEETING, Pa., January 20, 2021 (Globe Newswire) — INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated diseases, today announced the |
|
| January 20, 2021 |
Subject to Completion Preliminary Prospectus Supplement dated January 20, 2021 424B5 1 d113891d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-252256 The information in this prospectus is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any state or other jurisdiction where the o |
|
| January 20, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 20, 2021 Inovio Pharmaceuticals, Inc. |
|
| January 20, 2021 |
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS EX-99.1 Exhibit 99.1 In the preliminary prospectus supplement to be used in connection with a proposed public offering of shares of its common stock by Inovio Pharmaceuticals, Inc. (the “Company”), the Company provided the following updates or supplements to the description of certain aspects of the Company’s business, certain legal proceedings and certain risk factors provided in the Company’s pr |
|
| January 20, 2021 |
S-3ASR 1 d110733ds3asr.htm S-3ASR Table of Contents As filed with the Securities and Exchange Commission on January 20, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Inovio Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 33-0969592 (State or ot |
|
| January 4, 2021 |
EX-99.1 Exhibit 99.1 INOVIO and Advaccine Announce Exclusive Partnership To Commercialize COVID-19 DNA Vaccine Candidate, INO-4800, in Greater China Partnership Adds Asian Manufacturing Resource to INOVIO’s Global Manufacturing Consortium for INO-4800 INO-4800 Phase 2 Trial Fully Enrolled in China PLYMOUTH MEETING, Pa. and SUZHOU, China, Jan. 4, 2021 /PRNewswire/ – INOVIO (NASDAQ: INO), a biotechn |
|
| January 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2020 Inovio Pharmaceuticals, Inc. |
|
| November 16, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2020 Inovio Pharmaceuticals, Inc. |
|
| November 16, 2020 |
EX-99.1 Exhibit 99.1 INOVIO Announces Initiation of Phase 2 Segment of its Phase 2/3 Clinical Trial for its COVID-19 DNA Vaccine Candidate, INO-4800; Trial Will Be Funded by the U.S. Department of Defense PLYMOUTH MEETING, PA – November 16, 2020 – INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious |
|
| November 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICA |
|
| October 15, 2020 |
Termination of a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2020 Inovio Pharmaceuticals, Inc. |
|
| September 28, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2020 Inovio Pharmaceuticals, Inc. |
|
| September 28, 2020 |
EX-99.1 Exhibit 99.1 INOVIO Reports FDA Partial Clinical Hold for Planned Phase 2 / 3 Trial of COVID-19 Vaccine Candidate INO-4800 PLYMOUTH MEETING, PA – September 28, 2020 – INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, announced that the U.S. Food and Drug Administration |
|
| September 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2020 Inovio Pharmaceuticals, Inc. |
|
| August 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, I |
|
| August 10, 2020 |
Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. OTHER TRANSACTION AUTHORITY FOR PROTOTYPE AGREEMENT BETWEEN Inovio Pharmaceuticals, Inc. (Awardee) 660 W Germantown Pike Ste 11 |
|
| August 10, 2020 |
Exhibit 10.2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. AWARD/CONTRACT 1. THIS CONTRACT IS A RATED ORDER UNDER DPAS (15 CFR 700) RATING PAGE OF PAGES 1 [***] 2. CONTRACT (Proc. [***]. |
|
| June 25, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2020 Inovio Pharmaceuticals, Inc. |
|
| June 25, 2020 |
EX-99.1 Exhibit 99.1 INOVIO Receives $71 Million Contract From U.S. Department of Defense To Scale Up Manufacture of CELLECTRA® 3PSP Smart Device and Procurement of CELLECTRA® 2000 for COVID-19 DNA Vaccine • U.S. Government will support the scale-up of INOVIO’s proprietary intradermal DNA delivery device CELLECTRA® 3PSP to deliver INOVIO’s COVID-19 vaccine • INOVIO to report on interim US Phase 1 |
|
| June 3, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2020 Inovio Pharmaceuticals, Inc. |
|
| May 18, 2020 |
Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2020 Inovio Pharmaceuticals, Inc. |
|
| May 12, 2020 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2020 Inovio Pharmaceuticals, Inc. |
|
| May 12, 2020 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-237172 PROSPECTUS SUPPLEMENT (To Prospectus Dated March 31, 2020) $100,000,000 Common Stock We have previously entered into an At-the-Market Equity Offering Sales Agreement, or the Sales Agreement, with Stifel, Nicolaus & Company, Incorporated, or Stifel, relating to shares of our common stock offered by this prospectus |
|
| May 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, |
|
| May 1, 2020 |
United States securities and exchange commission logo May 1, 2020 Peter Kies Chief Financial Officer INOVIO PHARMACEUTICALS, INC. |
|
| May 1, 2020 |
United States securities and exchange commission logo May 1, 2020 Peter Kies Chief Financial Officer INOVIO PHARMACEUTICALS, INC. |
|
| April 24, 2020 |
CORRESP Brian F. Leaf (703) 456-8053 [email protected] VIA EDGAR April 24, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Attn: Tracey McKoy Terence O’Brien Re: Inovio Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2019 File No. 001-14888 Filed March 12, 2020 Ladies and Gentlemen: O |
|
| April 15, 2020 |
INO / Inovio Pharmaceuticals, Inc. DEFA14A - - DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
